Surgical and interventional therapies for pulmonary arterial hypertension (PAH) in appropriately selected patients have the potential to dramatically improve or, in some cases, cure PAH. These include atrial septostomy, a palliative procedure or bridge to transplantation in patients with refractory right heart failure, pulmonary thromboendarterectomy for pulmonary hypertension associated with chronic thromboembolic disease, and closure of congenital systemic-pulmonary shunts in patients with PAH but without significant pulmonary vascular disease. Lung transplantation should be considered for patients with all forms of PAH who demonstrate advanced or progressive disease.
The medical treatment of patients with pulmonary arterial hypertension (PAH) has undergone a tremendous evolution over the past decades and, more specifically, the past several years. Effective medical treatment options were nonexistent until the mid1990s when intravenous epoprostenol became available. More recently, several oral, inhaled, and intravenous medications have become available for use in patients with PAH. Regardless of the availability of medical therapies, when appropriate surgical and interventional therapies may offer the best long-term outcomes in carefully selected subsets of patients with PAH, and clinicians must seek to identify these patients.
Atrial septostomy (AS) is a potential option for bridging patients to transplantation and has been used in several countries as a palliative measure for patients with refractory right heart failure and PAH. Pulmonary thromboendarterectomy (PTE) offers the potential for a surgical cure in the subset of patients who have chronic thromboembolic pulmonary hypertension (CTEPH).
Lung transplantation or heart-lung transplantation offers definitive treatment for patients with all types of PAH. Finally, adult patients with congenital heart disease may be an underrecognized group of patients among physicians who care for adults with PAH and in whom surgical or catheter-based interventions may be appropriate. A brief review of the physiology of atrial and ventricular septal defects (ASDs, VSDs) is provided.
ATRIAL SEPTOSTOMY
AS has been used as a palliative measure in patients with PAH and severe right ventricular (RV) failure refractory to medical management. It involves the creation of an atrial septal defect, which leads to a right to left shunt and a reduction in volume and pressure overload of the RV. The immediate hemodynamic effect is an increase in cardiac output and a significant decrease in systemic arterial oxygen saturation. Multiple case series of AS have been reported [1] [2] [3] [4] [5] [6] [7] but larger studies examining longterm outcome have not been done. AS is considered a palliative treatment because it does not alter the pulmonary vascular resistance in either the short or the long term. 1 Patient characteristics, definitions of maximal medical therapy before resorting to AS, methods for performing AS, and postprocedure outcomes vary significantly among case series. Patients generally are New York Heart Association (NYHA) class III or IV with worsening symptoms on available medical therapy. Several case series were published before the availability of intravenous prostacyclin 1, 3, [5] [6] [7] but in the most recent series patients undergoing AS were on intravenous prostacyclin. 2, 4 With the decrease in arterial oxygen saturation expected after AS some institutions prefer a preprocedure hematocrit of 35 to 40%. 1, 7 A minimum resting, room air, oxygen saturation > 90% prior to AS has been recommended by some. 8 The creation of an atrial septal defect is most often accomplished by blade septostomy with or without balloon dilation or via graded static balloon dilation. [1] [2] [3] [4] [5] [6] [7] In both procedures, first a transseptal puncture is performed either with a Brockenbrough needle (Medtronics, Minn., MN, USA), or more recently, using a special radiofrequency perforation system. In blade septostomy, a Park blade is then used to make three to six incisions in the septum. The incisions may be followed by static balloon dilation or balloon AS if the defect size created with the blade is deemed inadequate. In static balloon dilation septostomy, successive balloons of increasing size are used to achieve progressive dilation of the orifice. A drop in systemic oxygen saturation of 5 to 10% is a generally accepted end point indicative of an adequate septal defect. Advantages of the blade method include a lower risk of intermediate to late spontaneous closure of the defect whereas the major disadvantage is the significant difficulty in controlling the size of the interatrial communication. Creation of an excessively large defect leads to a large right-to-left shunt with significant systemic desaturation and may lead to death within 24 to 48 hours of the procedure. 3, 7 The graded balloon dilation method allows improved control of the size of the defect at the expense of an increased incidence of spontaneous closure requiring repeat septostomy.
Symptomatic improvement has been reported in 50-85% of patients who survive AS. [1] [2] [3] [4] [5] [6] [7] Procedure-related death rates vary from 0 to 33% and may be related to the degree of experience with AS at the center or improved patient selection. Cardiac index consistently improved in patients who survived the procedure, with mean improvements from 31 to 85%. Repeat AS was required in 8 to 33%
1,2,7 and smaller ASD size was associated with an increased risk of spontaneous closure. In patients undergoing repeat cardiac catheterization 7 to 27 months after AS, no significant changes in mean pulmonary artery pressure (PAP) were seen. 1 At the time of follow-up catheterization, mean right atrial pressure (RAP) remained lower and mean left atrial pressure (LAP) remained elevated, with a sustained increase in cardiac index and a reduced systemic arterial oxygen saturation. Following AS most patients develop some degree of polycythemia, which, combined with the increase in cardiac output caused by the rightto-left shunt, leads to improved systemic oxygen delivery. The majority of patients, however, will require supplemental oxygen following AS. One-, 2-and 3-year survival rates were 80%, 73%, and 65%, respectively, in one series, but whether AS improves long-term survival in the current medical-therapy era remains to be determined. 1 In summary, AS remains a potential option for improving symptoms in patients with severe PAH and evidence of right heart failure despite maximal medical therapy. Patients with right heart failure who are NYHA III or IV, have a resting oxygen saturation of at least 90%, and are not anemic and in whom all other therapies have failed may be candidates for AS. Patients with the most advanced PAH, defined by a markedly elevated pulmonary vascular resistance (PVR), systemic arterial oxygen saturations < 80% at rest, and low cardiac output are high-risk candidates. The success of AS varies greatly and is likely dependent on both patient selection and the technical expertise of those performing the procedure.
PULMONARY THROMBOENDARTERECTOMY CTEPH is a relatively uncommon cause of PAH but is important to diagnose accurately because CTEPH is a potentially curable form of PAH. In the past it has been generally accepted that most patients who suffer acute pulmonary embolus (PE) and survive the initial event resolve their thrombus and suffer no long-term sequelae. But a recent report from the Thromboembolic Pulmonary Hypertension Study Group demonstrated a 3.8% incidence of symptomatic CTEPH at 2-year follow-up after an acute thromboembolic event. 9 The surgical approach for PTE is via a median sternotomy with cardiopulmonary bypass using circulatory arrest with deep hypothermia and it involves a true endarterectomy with dissection of well-organized thromboembolic material and part of the intimal layer of the pulmonary arterial bed. 10 The procedure should be distinguished from acute embolectomy for massive PE, which is not discussed here. Only centrally located thrombus is amenable to surgical intervention and patients with primarily microvascular disease should not undergo PTE. Surgery is considered technically feasible if the obstructing thrombi are not located distal to the lobar arteries or to the origin of the segmental vessels. 10 Although surgical mortality rates have decreased with increasing experience and improved perioperative care PTE remains a fairly high-risk intervention.
Diagnostic Tests Used to Determine Suitability for Pulmonary Thromboendarterectomy
Identifying surgically accessible disease is the principal step in selecting patients for PTE. Only lesions affecting central (main, lobar, or segmental) pulmonary arteries are amenable to surgical intervention. Patients with more distal disease affecting primarily small pulmonary vessels should be excluded from surgical consideration. Patients with other causes of pulmonary hypertension, such as idiopathic PAH (IPAH), must also be excluded. Pulmonary angiography is the preferred imaging modality for evaluating the extent of pulmonary vascular disease prior to surgery but several recent studies have also demonstrated the utility of computed tomography (CT) and magnetic resonance imaging (MRI) in evaluating patients before and after PTE.
Currently, ventilation/perfusion (V/Q) scanning is routinely performed during the initial evaluation of patients presenting with a new diagnosis of pulmonary hypertension. Any perfusion defects on the initial V/Q should raise the suspicion of PE or CTEPH and prompt further evaluation. Although V/Q scanning is an effective means of distinguishing patients with IPAH from patients with CTEPH it does not provide adequate anatomical information in patients undergoing evaluation for possible PTE.
11 V/Q scanning has been shown to significantly underestimate the severity of pulmonary arterial obstruction and hemodynamic compromise compared with conventional angiography. 12 Pulmonary angiography may be performed as part of a right heart catheterization (RHC) after appropriate pressure measurements and saturations have been obtained. To improve diagnostic accuracy, selective (i.e., both right and left) rather than nonselective (i.e., main) pulmonary artery angiography should be performed if a suspicion of pulmonary embolism exists. Pulmonary arterial webs, intimal irregularities, pouching, and abrupt narrowing or termination of major pulmonary vessels are classical findings in patients with CTEPH. 13 Reports on pulmonary angiography from the 1960s to the 1980s suggested a high incidence of complications, including death and arrhythmias, [14] [15] [16] and discouraged its use. With the advent of newer contrast agents, more recent studies have demonstrated that pulmonary angiography is a safe procedure that can be performed with few complications. [17] [18] [19] Our institutional experience has also been that angiography can be performed safely even in patients with severe pulmonary hypertension.
CT and MRI are alternatives to angiography that avoid the potential complications of conscious sedation and invasive catheterization. Angiography may be superior to CT scanning for identifying vascular distortion (38 vs 50%) and stenoses (35 vs 71.8%), but CT allows for evaluation of vessels that are not opacified during angiography due to stenoses or thrombus. 20 A series of 55 patients comparing helical CT with pulmonary angiography and magnetic resonance angiography (MRA) showed that CT may identify central vessel disease more accurately (accuracy 0.79) than angiography (accuracy 0.74) and MRI (accuracy 0.39). 21 A recent series of 32 patients comparing CT angiography (CTA) with MRA demonstrated that CTA is superior for visualization of thrombotic wall thickening and intraluminal webs, whereas MRA allowed better visualization of abnormal vessel tapering. Overall, the imaging modalities were comparable and both allowed identification of surgically accessible disease as confirmed by subsequent PTE. 22 Breathhold MRI may provide detailed morphological assessment and limited information on functional improvement when performed before and after PTE. In 32 patients evaluated preoperatively, MRA was inferior to conventional angiography in identifying the number of patent vessels but correctly identified all patients as candidates for PTE. Cine MRI also provided information on degree of RV dysfunction and pulmonary artery blood flow measurements with documentation of significant improvement after PTE. 23 Pulmonary angiography is the gold standard for determining the presence of surgically accessible disease but CTA and MRA may provide important information that complements the data obtained from conventional angiography, including detailed information about vessel anatomy distal to occlusive thrombus, the presence of lymphadenopathy, and the presence of any pulmonary parenchymal abnormalities.
Selection Criteria for Pulmonary Thromboendarterectomy Selection criteria for PTE have not been reported in detail in most studies. The following basic criteria have been proposed for selection of patients undergoing PTE: (1) NYHA class III or IV functional symptoms; (2) a preoperative PVR > 300 dyn s/cm 5 (slightly less than 4 Wood's units); (3) surgically accessible thrombus in the main, lobar, or segmental pulmonary arteries; (4) no severe comorbidities. 24 Ideally candidates for PTE should have at least 50% of the pulmonary arterial vasculature obstructed and the obstructions should be at least as proximal as the lobar artery origins. Patients with obstruction beginning at the origins of the segmental arteries may have suboptimal results because of inadequate relief of obstruction after surgery. 10 Coronary angiography may be necessary in some patients to rule out the presence of concomitant coronary artery disease. 10 Patients with associated renal disease, parenchymal lung disease, and coronary or cerebrovascular disease clearly present an increased surgical risk but are not excluded at all centers. Other factors associated with increased risk of death with PTE include age > 70 years, marked obesity, severity of preoperative elevation of PVR, and severity of preoperative RV dysfunction and NYHA class IV symptoms. [24] [25] [26] PTE has been performed successfully in a patient with preoperative cryoagglutinins and in two patients with sickle cell disease.
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Outcome after Pulmonary Thromboendarterectomy PTE leads to a marked reduction in PAP and improvement in cardiac output (CO) in most patients. A reduction in mean PVR by as much as 70% may be seen with a 40% reduction in mean PAP and a 50% increase in mean CO. [29] [30] [31] Most patients attain a mean PAP in the range of 20 to 30 mm Hg and a near-normal CO. Echocardiographic evaluation of patients undergoing PTE has shown a marked postoperative reduction in RV size and improvement in systolic function. Normalization of interventricular septal motion with improvements in LV systolic and diastolic function and CO has been observed. 32 Gas exchange also improves after PTE due largely to a reduction in V A /Q mismatching and improvements in CO. In a group of eight patients with moderately severe V A /Q mismatch preoperatively PTE led to a near-normal V A /Q distribution associated with a significant improvement in resting pO 2 though diffusion capacity did not change. 33 Most patients who survive to hospital discharge after PTE report significant improvements in dyspnea and exercise tolerance. Patients usually begin to notice symptomatic improvement $ 2 weeks after surgery and may continue to note functional improvement as long as 9 to 12 months postoperatively. 24 More than 90% of patients improve from NYHA class III or IV symptoms preoperatively to class I or II after PTE. [29] [30] [31] 34 Early attempts at PTE were associated with an in-hospital mortality rate of 22% 35 but more recent reports show surgical mortality rates as low 9% in experienced centers, likely due to improvements in patient selection, surgical technique, and perioperative management. 10, 24, 29, 36 Some centers continue to report in-hospital mortality rates as high as 24%. 26, 37 Major causes of early patient deaths include persistent pulmonary hypertension and reperfusion lung injury, accounting for over 50% of deaths in most series. 29, 38 Other causes of in-hospital death include arrhythmias, cerebrovascular events, bleeding, and multiorgan failure. 38, 39 The reperfusion lung injury appears be a localized form of high-permeability lung injury associated with hypoxemia and new radiographic infiltrates in areas of reperfused lung within 48 hours of surgery. It remains poorly understood but appears to be neutrophil mediated and may be prevented in some patients by the administration of Cylexin at the start of surgery. 39 Avoiding the use of positive inotropic agents and using a lungprotective ventilatory strategy with low tidal volumes and low peak pressures postoperatively has been shown to decrease the incidence of pulmonary edema and decrease mortality. 40 Long-term survival data are limited, but Archibald et al reported a 75% 6-year survival rate for patients undergoing PTE at University of California, San Diego (UCSD) between 1970 and 1994 who survived to hospital discharge. 41 Most common causes of late death were persistent PAH or recurrent embolic events.
Reoperation after Pulmonary Thromboendarterectomy
Although most patients experience stable long-term symptomatic and hemodynamic improvements after PTE, recurrent symptoms associated with worsening pulmonary hypertension occur in some patients. Mo et al reported the institutional experience with repeat PTE at UCSD from 1989 to 1998, 42 and redo operations represented 1.5% of all cases. Operative mortality was comparable to primary operation at 7.7% but the postoperative hemodynamic improvements were notably less than after primary operation. The reported functional improvement, however, was comparable to primary operation, with 83% of patients experiencing significant benefit. Risk factors for needing repeat PTE include an initial unilateral PTE, documented thrombophilia, ineffective caval filtration, and suboptimal anticoagulation. It is thus suggested that bilateral primary PTE, life-long anticoagulation, and appropriate placement of an inferior vena cava (IVC) filter may prevent the need for reoperation in most patients.
BALLOON ANGIOPLASTY FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
In the small group of patients with significant thromboembolic disease in large pulmonary vessels beyond the reach of the surgeon, balloon angioplasty has been shown to be safe and effective. In the largest series to date, Feinstein et al reported the use of balloon angioplasty in 18 patients with thromboembolic disease. 43 Two patients had proximal disease but were not candidates for PTE and 16 patients had distal thromboembolic disease. Patients had significant improvement in 6-minute walk distance and functional status improved from mean NYHA class 3.3 to 1.8. Sixty percent of patients developed reperfusion pulmonary edema and one death was attributed to right heart failure. Despite improvement in performance and functional class, due to the small number of potential candidates and the special expertise required pulmonary angioplasty has not gained widespread acceptance and is not available in most centers.
LUNG AND HEART-LUNG TRANSPLANTATION
The first successful heart-lung transplantation (HLT) was performed in 1981 in a patient with pulmonary vascular disease due to IPAH. 44 Since that initial success, lung transplantation (LT) has been a mainstay of treatment of end-stage PAH refractory to medical treatment. From January 1995 to June 2003, 457 lung transplants were performed for IPAH 45 and IPAH was the indication for 4.2% of transplants performed during that time period. Pulmonary vascular disease, either in the setting of congenital heart disease (CHD)/Eisenmenger's syndrome or in the setting of IPAH remains the most common indication for a combined HLT. From 1982 to 2003, 76.4% of all HLT procedures were performed for this indication. Of note, the number of lung transplants being performed for IPAH has declined by 15% during this interval, likely due to the availability of better medical therapeutic options. The number of combined HLTs being performed has been declining since 1996 and only 76 HLTs were recorded for 2002. This decline may be attributable in part to a shift to bilateral lung transplantation (BLT) being performed for the same indications and the realization that transplant may be safely delayed in many adults with PAH due to CHD. However, LT and HLT remain important treatment options for patients who are not candidates for other surgical treatments and who are failing medical management.
Patient Referral and Listing for Transplant
The timing of transplantation for PAH depends on several factors, including the patient's primary diagnosis, stage of disease, response to medical therapy, suitability for other surgical interventions, and local waiting times for donors. A good understanding of the natural history of the underlying disease with and without transplantation can help define the timing of referral. As a general principle, referring physicians should be encouraged to refer their patients for transplant evaluation sooner rather than later. Emergent transplants are generally not performed for lung transplantation because they may be for other solid organs. Patients need to be stable enough to undergo the required pretransplant evaluation and as a general rule, evaluation should be initiated for patients experiencing deterioration in functional status despite optimal medical therapy who have a life expectancy of less than 2 years.
As of May 2005 the allocation of donor lung offers in the United States is based on a Lung Allocation Score (LAS), which is assigned to each patient awaiting transplant. The LAS is calculated using the following measures: (1) waitlist urgency measure, (2) post-transplant survival measure, (3) transplant benefit measure. The waitlist urgency measure and post-transplant survival measure are developed using Cox proportional hazards models. Factors used to predict the risk of death on the transplant list include forced vital capacity, age, body mass index, insulin-dependent diabetes, NYHA functional class, 6-minute walk distance, ventilator use, and diagnosis. Factors that predict survival after transplant include forced vital capacity, ventilator use, age, creatinine, NYHA functional class, and diagnosis. These clinical variables are used to calculate the probability of 1-year survival for a patient who is on the waiting list as well as the patient's predicted 1-year survival after transplantation.
Clinical variables for patients awaiting LT or HLT need to be updated at least once every 6 months in transplant candidates but can be updated more frequently at the discretion of the transplant center. It is unclear how the new lung allocation system will impact patients with PAH with or without CHD. The LAS does not account for clinical events such as hemoptysis or syncope and thus these potential warning signs in ill PAH patients may not be reflected in their LAS score. However, in cases where the transplant center feels that an individual's LAS underestimates the person's clinical severity an appeal can be made to the UNOS (United Network for Organ Sharing) Lung Review Board for adjustment of the LAS.
Transplantation in Patients with Pulmonary
Arterial Hypertension without Congenital Heart Disease Before the availability of intravenous epoprostenol, the estimated median survival of patients with IPAH was 2.8 years from the time of diagnosis. 46 With the advent
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of intravenous epoprostenol these statistics have changed significantly and transplant may be delayed in some patients. Sustained benefit with improvements in mean pulmonary arterial pressure (mPAP), PVR, and CO may be seen over several years of therapy in many patients. 47, 48 Unfortunately, these studies still show mortality rates of $ 50% at 3 years follow-up. Intravenous epoprostenol therefore does not eliminate the eventual need for transplantation in many of these patients. 47 Current guidelines recommend that all patients with PAH be referred to a transplant center with experience in vasodilator therapy and all patients should be evaluated for vasodilator therapy and alternate surgical options before proceeding to transplantation. 49 Patients should be considered for transplantation if they remain in NYHA class III or IV functional status despite optimal medical management. Hemodynamic parameters generally accepted as indications for transplant evaluation include an mPAP > 55 mm Hg, mean right atrial pressure (mRAP) > 10 mm Hg and a cardiac index (CI) < 2.0 L/min/m 2 .
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Transplantation in Patients with Pulmonary Arterial Hypertension with Congenital Heart Disease
Patients with PAH due to CHD and Eisenmenger's syndrome have significantly better outcomes with medical therapy than patients with PAH without CHD. These patients tolerate much higher pulmonary artery pressures with less elevation in RAP and a better cardiac index compared with patients with other causes of PAH. 50 Elevated PAPs seen in patients with PAH without CHD are tolerated poorly and are associated with significant RV dilation and systolic dysfunction compared with patients with Eisenmenger's physiology. An echocardiographic study of adult patients with Eisenmenger's syndrome suggested that the hearts of adult patients with Eisenmenger's physiology are morphologically more similar to the normal fetal heart than to a normal adult heart. 51 As in the fetal circulation, patients with Eisenmenger's syndrome have equal LV and RV systolic pressures, equal RV and LV wall thickness, elevated PVR, and arterial hypoxemia. Because of the equal RV and LV pressures the normal regression of RV wall thickness following delivery never occurs and the heart is thus better able to tolerate near-systemic or systemic pulmonary pressures. Adult patients with acquired causes of PAH presumably undergo normal regression of the RV wall thickness after delivery and are therefore unable to tolerate similar elevations in PVR without progression to right heart failure.
In general, the degree of hemodynamic derangements is less helpful in patients with PAH with CHD in determining the timing of transplant evaluation because many patients do well with medical therapy alone and each patient must therefore be considered on an individual basis. 52 Current guidelines recommend consideration for transplant for patients with severe, progressive symptoms and NYHA class III or IV functional status despite optimal medical management. 49 Ideally, patients should complete transplant evaluation prior to onset of significant symptoms, and subsequent follow-up at an experienced transplant center can allow for listing once clinical deterioration occurs.
Clinical Evaluation for Lung or Heart-Lung Transplantation
Many diagnostic studies, in addition to a thorough history and physical, are required in the evaluation of patients being considered for LT or HLT. These include full pulmonary function testing, a 6-minute walk test, chest imaging, and a quantitative V/Q scan in candidates for single-lung transplantation (SLT). Echocardiograms are performed to evaluate right and left heart function, including assessment for valvular heart disease, intracardiac shunts, and the presence or absence of significant LV dysfunction. Coronary angiography or dobutamine stress echocardiography (DSE) is indicated in at-risk patients to rule out occult coronary artery disease. Ideally preoperative serum creatinine level is less than 1.5 mg/ dL and 24-hour creatinine clearance should be greater than 50 mL/min. 53 Patients in whom impaired renal function is attributable to poor cardiac output due to PAH may be exceptions to this rule because creatinine clearance would be expected to improve after transplantation. Hyperbilirubinemia of greater than 2.5 mg/ dL has been identified as a marker of poor outcome and increased risk of perioperative complications in patients with PAH undergoing transplantation. 53, 54 Extensive blood work including a complete blood count, platelet count, coagulation profile, ABO/Rh and HLA typing, and a panel reactive antibody (PRA) screen is also performed. A PRA > 10% has been associated with worse outcome after transplantation. 45 Screening for infectious diseases including hepatitis, human immunodeficiency virus (HIV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), and herpes simplex virus (HSV) is also performed prior to transplantation.
Clinical symptoms suggestive of gastroesophageal reflux disease (GERD) or gastroparesis should be evaluated with esophagogastroduodenoscopy (EGD), esophageal manometry, or esophageal pH monitoring as clinically indicated. Routine health maintenance exams, including Pap smear, mammography, and colon cancer screening should be performed according to the guidelines established for the general population. A thorough endocrine evaluation is performed to ensure adequate thyroid and adrenal function and to assess the extent of any metabolic bone disease. Osteoporosis leading to fractures is an increasingly recognized cause of debilitation and pain post-transplant, and any significant bone demineralization diagnosed pretransplant should be aggressively treated. Nutritional status should be optimized prior to transplantation to achieve a weight within 70 to 130% of ideal body weight 49 and thus optimize outcomes.
A psychosocial assessment should be performed in all patients to determine their ability to cope with stress and to assess the adequacy of the social support system available to the patient. A primary support person who will remain actively involved in care of the patient during the transplant process must be identified. Patients with a history of drug or alcohol abuse must demonstrate abstinence for at least 6 months due to the high rate of noncompliance in this population. Recommended exclusion criteria for LT and HLT have been published elsewhere 49 but include advanced age, major organ dysfunction, recent history of malignancy, and infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).
Type of Transplant Procedure
Transplant procedures performed for PAH have traditionally included BLT and HLT. SLT is less commonly performed for PAH due to concerns about V/Q mismatching in the native lung. Patients with IPAH accounted for 1.1% of SLT recipients, 7.6% of BLT recipients, and 24.3% of all recipients of HLT in the registry. 45 The type of procedure that patients with PAH were likely to receive varied significantly among transplant centers in the past. HLT was the first successful procedure for PAH and is still preferred at some centers, but given the persistent shortage of organs BLT is the preferred procedure in most patients with IPAH. A recent survey of transplant centers revealed that 81% would choose BLT for a 50-year-old woman with IPAH and a right ventricular ejection fraction (RVEF) of 20%. 55 The severe RV dysfunction seen in PAH is usually reversible after LT thus eliminating the need for combined HLT in these patients. 56 RV dimensions and function returned to normal at 3-month follow-up after LT, and the interventricular septum returned to its normal position. Compared with SLT, BLT results in better hemodynamics, less V/Q mismatch, and fewer perioperative complications. 57, 58 By providing better overall lung function BLT may be protective against the physiological manifestations of chronic rejection and appears to offer a better long-term post-transplant survival compared with SLT. 45 Patients with simple CHD and PAH can successfully undergo BLT with cardiac repair in most cases but those with complex CHD will likely require HLT. Whether HLT offers a survival benefit over either SLT or BLT is not clear. Some studies show no benefit in survival [59] [60] [61] whereas others suggest improved survival with HLT. 62, 63 Patients listed for combined HLT may experience longer waiting times and their overall survival may thereby be adversely affected.
There are no randomized studies to determine the optimal transplant procedure for PAH and, given the scarcity of organs, such studies are unlikely to be performed in the future. Based on the data currently available, BLT appears to be the transplant procedure of choice in most patients with PAH. The decision about which procedure is most appropriate for each individual patient, however, should be left to the centers with extensive experience in transplantation.
Survival and Functional Outcome Following Transplantation
The most recent report from the International Society for Heart and Lung Transplantation (ISHLT) in 2004 shows overall survival rates for all patients undergoing transplantation for PAH from January 1990 to June 2002 of 64.8% at 1 year, 54.4% at 3 years, 45.4% at 5 years, 37.2% at 7 years, and 20.3% at 10 years. 45 Survival at 1 year post-transplantation is lowest for patients with PAH compared with all other subgroups, including patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). By 10 years post-transplantation, however, survival rates for patients with PAH are better than those for patients undergoing transplantation for COPD and IPF (18.2% and 17.5%, respectively). Across all transplant recipients survival rates are similar for SLT and BLT during the first year. At longer follow-up, the survival rates gradually diverge, with improved survival among patients receiving BLT. Whether this difference is actually due to the type of procedure or due to differences in age and underlying diagnosis among patients is not clear. 45 For patients with PAH, there was no significant difference in survival at 10-year follow-up between patients receiving SLT versus BLT. Among adult patients undergoing HLT, survival rates were 62% at 1 year, 41% at 5 years, and 26% at 10 years. Among patients with pulmonary vascular disorders, survival at 10 years is comparable between patients with IPAH and Eisenmenger's syndrome and both groups fare better than patients with other congenital anomalies. Major causes of early deaths after transplantation include technical complications, graft failure, and infection. Major causes of late deaths include graft failure, infection, and bronchiolitis obliterans (BOS). Although any injury to the lung, including infection, ischemia, or reperfusion injury, may contribute to the development of BOS, the relationship of BOS to the recipient's diagnosis and type of transplant procedure is unknown. 64 Approximately 80% of patients have no activity limitation when surveyed at 1-year, 3-year, 5-year, and 7-year post-transplantation. Common causes of morbidity after transplantation include renal dysfunction, diabetes mellitus, systemic hypertension, hyperlipidemia, skin and lymphoid malignancies, and BOS. 45 A survey of Swiss lung transplant recipients showed rates of depression and anxiety among transplant patients that were comparable to the general population at 1.6 to 9 years post-transplant. Clinically significant or borderline depression was present in 10% of patients and 28% had anxiety. Patients with good social support were less likely to report symptoms of anxiety or depression. 65 In most studies, transplant recipients report dramatic improvements in quality of life and are satisfied with their decision to undergo transplantation. 66, 67 CONGENITAL HEART DISEASE IN THE ADULT PULMONARY ARTERIAL HYPERTENSION PATIENT An increasing number of patients with CHD are now surviving into adulthood. Although most adult patients with complex CHD have undergone surgical corrective procedures during childhood, some adult patient with forms of simple CHD have never been diagnosed. An increasing number of patients are diagnosed with a congenital heart defect by RHC performed for a new diagnosis of pulmonary hypertension. The most common defects diagnosed in adulthood are ASDs and small VSDs. Although the term Eisenmenger's syndrome traditionally referred to patients with unoperated VSDs, similar physiology may develop in the patient with an unoperated ASD and the term here is used interchangeably to denote PAH in the setting of CHD.
Evaluation of the patient with PAH and suspected CHD should include echocardiography and RHC to evaluate hemodynamics, confirm the presence of a septal defect, and measure the degree of intracardiac shunting. Oxygen saturations are obtained from the high and low superior vena cava (SVC), IVC, right atrium (RA), RV, right and left pulmonary arteries (PAs), and, if necessary left atrium (LA) to allow calculation of the PVR and pulmonary to systemic flow ratio (Qp:Qs). 68 A 10% step-up in RA saturation is usually indicative of a significant atrial left to right shunt. Qs represents systemic blood flow (cardiac output) whereas Qp represents pulmonary blood flow. The calculation of Qs and Qp is accomplished using data from the oximetry run. 
VO 2 is oxygen consumption and is either measured using a metabolic cart or estimated from age, gender, and heart rate. The mixed venous saturation is measured from the chamber immediately proximal to the shunt (RA for a VSD and calculated in EQ #3 for an ASD). CO 2 represents oxygen content. In the normal patient, pulmonary blood flow nearly equals systemic blood flow except for the small physiological shunt resulting from the emptying of coronary and bronchial blood into the LV and RA or pulmonary veins. A Qp:Qs of 1 to 1.5 is considered a small shunt that may not require further intervention. A Qp:Qs greater than 1.5 may indicate a hemodynamically significant shunt, and further consideration for closure of the defect is indicated. 68 Atrial Septal Defects ASDs account for 7 to 10% of all CHD but account for nearly 30% of CHD in adults. 69 The incidence is nearly twofold higher in women compared with men. The three types of ASDs are, in order of frequency, secundum, primum, and sinus venosus ASDs. Secundum defects are due to an absence of tissue in the fossa ovalis, are in the middle portion of the atrial septum, and account for 75% of ASDs. 70 Primum defects generally occur in the inferior atrial septum just superior to the inlet portion of both atrioventricular valves and account for 15% of ASDs. Primum defects tend to be more complex lesions and may be associated with significant mitral regurgitation. Sinus venosus defects account for only 5 to 10% of ASDs and are generally located at the posterosuperior atrial border adjacent to the SVC and often are associated with anomalous drainage of the pulmonary veins. Even without anomalous pulmonary venous drainage, blood from the right pulmonary veins often flows preferentially through the atrial defect to the RA and RV whereas blood from the left pulmonary veins flows into the LA and LV.
Secundum, primum, and sinus venosus ASDs allow a left to right shunt at the atrial level that results in right atrial and ventricular volume overload. The degree of shunting is related to the relative compliance of the right and left ventricles, to the size of the defect, and to the PVR relative to the SVR. 71 With progressive increases in PVR and PAP, a right to left shunt develops. Longstanding volume overload of the right heart can then lead to progressive RA and RV dilation occurs and eventually LV dysfunction due to altered LV chamber geometry and decreased preload. 72 Although only 5 to 10% of patients with unoperated ASDs go on to develop significant PAH and Eisenmenger's physiology, some degree of elevation in PAP may be seen in a large proportion of patients with unoperated ASDs. In one study of 706 patients with isolated secundum defects, 52% of patients over age 30 had sPAP > 32 mm Hg and 16% of patients over age 30 had PVR > 5 U. 73 Indications for ASD closure include a large left to right shunt (Qp:Qs > 1.5), RV dilation, progressive pulmonary hypertension, and/or an episode of paradoxical embolus. 70 In general, small ASDs less than 5 mm do not require closure. The presence of atrial fibrillation/flutter in an older patient is not an indication for closure because the patient over age 40 with preoperative atrial fibrillation is unlikely to convert to sinus rhythm after closure. [74] [75] [76] However, recent studies do not show an increased incidence of complications of transcatheter ASD closure in patients with atrial fibrillation who have other indications for closure. 77 In the past, closure of atrial septal defects was accomplished surgically via placement of a Dacron or pericardial patch. Currently, device closures are preferred for simple defects without associated valvular pathology. The Amplatzer Septal Occluder (AGA Med. Corp., Golden Valley, MN, USA) is a self-expandable, double-disc device that is approved for closure of secundum ASD's. 78 Complications of device placement usually occur early and include device malposition and device embolization. Several studies suggest few long-term complications in patients followed for 1 to 9 years after placement. 79, 80 Primum defects generally require surgical patch repair with concomitant suture repair of the mitral valve cleft. 70 Although younger patients with unoperated ASDs have relatively normal pulmonary vasculature, many patients older than age 40 present with significant pulmonary hypertension at their initial evaluation. [81] [82] [83] These patients may have small left to right shunts or may have progressed to Eisenmenger's physiology. In the presence of a large left to right shunt, patients with mild pulmonary hypertension would be expected to benefit from ASD closure with normalization of PA pressures. 69, 83 Patients with elevated PA pressures and Qp:Qs < 2.0 generally should only be considered for ASD closure if a vasoreactivity trial during RHC suggests some reversibility of their pulmonary hypertension. Patients with severe pulmonary hypertension and a right to left shunt are poor candidates for closure because surgical mortality is high. Moreover, elimination of the shunt leads to minimal long-term improvement in PVR in patients who survive surgery. 81 Ventricular Septal Defects Ventricular septal defect is the most common CHD diagnosed in infants and children and accounts for 10% of CHD diagnosed in adults. The size of the defect and the PVR:SVR ratio determines the degree of symptoms: large VSDs generally present with congestive heart failure in infancy but patients with single small and moderate-sized VSDs may survive into adulthood with relatively few symptoms. 84 Perimembranous defects lie adjacent to the tricuspid annulus in the region of the anteroseptal commissure and account for 80% of VSDs whereas muscular VSDs account for only 5 to 20% and are usually located in the midmuscular region. Subpulmonary defects account for 5 to 10% and are located immediately beneath the pulmonary and aortic valves. The septal defect causes a left to right shunt with volume overload of the LA, both ventricles, and pulmonary arteries. Small VSDs produce only a small left to right shunt with Qp:Qs < 1.5 and usually do not cause symptoms or hemodynamic changes over time. 84 In contrast, moderate-sized and large VSDs measuring over 1 cm 2 or larger than 75% of the aortic diameter are associated with large left to right shunts leading to RV hypertrophy and progressively worsening PAH over time.
Ten to 15% of adults with unoperated VSDs develop severe fixed PAH. Outcome is poor for surgical closure of VSDs if the PVR:SVR ratio is ! 0.7 and/or the PVRI (pulmonary vascular resistance index) > 7 WU 2 . 85, 86 Patients with bidirectional shunts are not good candidates for closure either and should be considered for HLT once signs of decompensated RV failure develop. Patients with moderate pulmonary hypertension who are able to maintain a Qp:Qs greater than 1.8 and a normal oxygen saturation may be considered candidates for VSD closure. 86 Perimembranous and subpulmonary defects may be closed surgically with a low risk of complications. Muscular VSDs and postoperative residual defects may be closed via a transcatheter approach. A series of 170 children undergoing device closure of muscular and postoperative residual defects showed successful placement of 99% of devices attempted with a significant decrease in shunting and VSD size. 87 At a median follow-up of 24 months, 6% of devices had explanted. A recent series of 75 children undergoing closure of small muscular VSDs with the Amplatzer VSD occluder (AGA Med. Corp., Golden Valley, MN, USA) showed a procedure-related major complication rate of 10.7% and a 92% complete closure rate at 12 months. 88 
CONCLUSION
Although medical therapy will continue to be the mainstay of treatment for most patients with PAH, several surgical options exist that provide excellent results in the appropriately selected patient. The clinician who cares for patients with PAH must carefully screen for all potentially surgically correctable causes of PAH and refer patients to specialized centers once a diagnosis has been made. AS is a difficult procedure with variable results but may be considered as a bridge to transplant in patients with advanced PAH refractory to medical management. PTE or balloon angioplasty are relatively high-risk procedures but in experienced centers can yield acceptable results in most patients. Consideration for PTE and appropriate referral should be made for all patients with CTEPH due to proximal obstructing lesions. LT and HLT continue to be the primary surgical options for most patients with advanced and progressive PAH who have failed all other interventions. Reported functional outcomes are excellent in most patients although the long-term morbidity and mortality rates associated with transplantation remain high. Transplantation should be considered for patients with progressive PAH and worsening symptoms on optimal medical therapy who have disease not amenable to other curative surgical procedures. Although a certain proportion of patients may ultimately be deemed ineligible for transplant due to the presence of significant medical or social problems every patient deserves an evaluation at a transplant center. Only an experienced transplant center can determine eligibility for transplantation after a thorough multidisciplinary workup. The clinician should therefore refer patients to a transplant center early in their disease course to allow ample time for the evaluation to be performed. RHC continues to be an essential part of the evaluation of the patient with newly diagnosed pulmonary hypertension, both to accurately describe the severity of disease and to help identify an underlying etiology. The pulmonologist should think about undiagnosed CHD in adult patients who present with complaints of dyspnea, poor exercise tolerance, syncope, or palpitations. As the awareness of adult CHD increases so does the number of patients being diagnosed with congenital shunts later in life.
